Otsuka Pakistan Limited (PSX: OTSU)

Market Cap	1.62B
Revenue (ttm)	3.16B
Net Income (ttm)	-4.76M
Shares Out	12.10M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,247
Open	131.25
Previous Close	131.90
Day's Range	131.00 - 139.80
52-Week Range	75.00 - 185.89
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 12, 2024

About Otsuka Pakistan

Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company’s products include electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products, such as aminoleban oral, proten gold, pan-amin G, aminoleban injection, and aminovel 600; and therapeutic drugs, which include mucosta ta...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 362
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: OTSU

Financial Performance

In 2024, Otsuka Pakistan's revenue was 3.16 billion, an increase of 4.24% compared to the previous year's 3.04 billion. Losses were -4.76 million, -33.91% less than in 2023.